## CBOE: Cboe Global Markets, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 -1.0% below STRENGTH zone (4.0-10.0%); PEG 2.09 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($238.96)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Cboe Global Markets (CBOE) Valuation After Barclays Upgrade on Derivatives Growth and Strategic Refocus**
- Source: Simply Wall Street | 20251216T140812 | Somewhat-Bullish | Relevance: 100%
- Barclays upgraded Cboe Global Markets (CBOE) to Overweight, citing strong performance in its index options and increased retail options activity. Despite a robust share price run and near-record highs, the company's valuation is debated, with Simply Wall St's narrative suggesting it's 5.8% undervalued, whereas a DCF model indicates it's overvalued. The article highlights Cboe's consistent double-digit revenue growth in its Data Vantage segment and strategic refocus on core derivatives.

**2. Cboe Global Markets (CBOE) Valuation After Barclays Upgrade on Derivatives Growth and Strategic Refocus**
- Source: Simply Wall Street | 20251216T140119 | Somewhat-Bullish | Relevance: 100%
- Barclays upgraded Cboe Global Markets (CBOE) to Overweight, citing its strong index options engine, increased retail options activity, and a sharpened focus on core derivatives. Despite a strong performance year-to-date and near-record highs, the stock's valuation is a key debate, showing a narrative fair value of $262.08 (moderately undervalued) versus a DCF model's $201 (overvalued). The narrative emphasizes Cboe's double-digit revenue growth in Data Vantage and operational efficiencies, while the DCF model suggests potential overvaluation if growth or margins underperform.

**3. Europe Equities Trade Reporting Services | Cboe**
- Source: Cboe Global Markets | 20251217T060759 | Somewhat-Bullish | Relevance: 100%
- Cboe Europe offers BXTR, a suite of Trade Reporting Services designed to standardize OTC data and help firms meet regulatory requirements under MiFID II. This includes on-exchange and OTC reporting, dissemination of MTF trades, and pre-trade transparency quoting. The article details the steps for new and existing participants to go live with the services, covering documentation, connectivity, and testing.

**4. Thrivent Financial for Lutherans Has $27.24 Million Position in Cboe Global Markets, Inc. $CBOE**
- Source: MarketBeat | 20251216T135219 | Neutral | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its stake in Cboe Global Markets, Inc. (NASDAQ:CBOE) by 44.3% in the second quarter, now owning 116,859 shares valued at $27.24 million. This move comes as Cboe Global Markets reported strong quarterly earnings, beating consensus estimates with an EPS of $2.67 and a 13.8% year-over-year revenue increase. The company also recently paid a quarterly dividend of $0.72 per share, and analysts maintain a "Hold" rating with an average target price of $245.15 for the stock.

**5. Cboe Global Markets (CBOE) Valuation After Barclays Upgrade on Derivatives Growth and Strategic Refocus**
- Source: Sahm | 20251217T050730 | Somewhat-Bullish | Relevance: 97%
- Barclays has upgraded Cboe Global Markets (CBOE) to Overweight, citing strong performance in index options, high retail options activity, and a strategic refocus on core derivatives. Despite CBOE's shares nearing record highs, trading at a modest discount to analyst targets, and displaying a rich intrinsic valuation, the company's valuation is debated. While a narrative valuation suggests a modest upside to $262.08, a discounted cash flow (DCF) model indicates the stock may be overvalued at around $201 per share.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Barclays | $302 | $273 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Barclays | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (+0.0%)
- Blackrock Inc.: 9.0% (-2.7%)
- Alliancebernstein L.: 6.1% (-31.2%)
- State Street Corpora: 4.5% (+2.1%)
- FMR, LLC: 4.3% (+62.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.09 elevated, pricing in significant growth expectations. Forward P/E 22.8x stretched relative to 5% growth. Quality metrics strong (ROE 22%, margin 21%). Analyst sentiment positive (1 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.0B |
| Beta | 0.35 |
| 52W Range | $187.30 - $262.98 |
| Short Interest | 3.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.09 |
| Forward P/E | 22.8 |
| Current P/E | 23.9 |
| YoY Growth | 5.1% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at -1.0% (minimal 5-day change). Below STRENGTH zone by 5.0pp (needs >4.0% for momentum thesis). Underperforming sector by 3.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). MACD histogram bearish (-0.92), momentum weakening. RSI neutral at 45. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.04% (CS: 31) | Neutral |
| RSI_14 | 45.0 | Neutral |
| MACD Histogram | -0.92 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 1.059x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $248.62
- **Stop Loss:** $238.96 (3.9% risk)
- **Target:** $258.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 73
- **Position Value:** $18,149.26
- **Portfolio %:** 18.15%
- **Risk Dollars:** $712.50
- **Risk Per Trade:** 0.71%
- **Modifiers:** L1 95% | L2 75% | Combined 0.71x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-06 (Est: $2.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.53 | $2.67 | +5.6% |
| 2025Q2 | $2.44 | $2.46 | +0.6% |
| 2025Q1 | $2.36 | $2.50 | +5.8% |
| 2024Q4 | $2.12 | $2.10 | -0.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*